Madrigal Pharmaceuticals
$246.77
31
+$13.6+5.84% 今天
统计数据
当日最高
247.7
当日最低
233.5
52周最高
299.98
52周最低
119.76
成交量
92,134
平均成交量
281,517
市值
5.37B
市盈率
-
股息收益率
-
股息
-
即将到来
收益
6Nov预期
预期每股收益
-7.048399
实际每股收益
N/A
人们还关注
此列表基于关注MDGL的Stock Events用户的观察列表。这不是投资建议。
竞争者
这个列表是基于最近市场事件的分析。这不是投资建议。
Viking Therapeutics
VKTX
市值7.1B
Gilead Sciences
GILD
市值98.35B
Galmed Pharmaceuticals
GLMD
市值2.18M
Agios Pharmaceuticals
AGIO
市值2.61B
FibroGen
FGEN
市值36.71M
Axsome Therapeutics
AXSM
市值4.27B
Novartis
NVS
市值244.75B
分析师评级
309.33$平均价格目标
最高估值为 $390。
来自过去6个月内的 8 个评级。这不是投资建议。
买入
50%
持有
38%
卖出
13%
关于
Health Technology
Pharmaceuticals: Other
Manufacturing
Pharmaceutical Preparation Manufacturing
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Show more...
首席执行官
Rebecca Taub
员工
376
国家
US
ISIN
US5588681057